The medical aesthetics industry is highly fragmented and growing fast. Here's how experienced acquirers are consolidating independent med spas into scalable, exit-ready platforms.
Find Med Spa Platform TargetsThe U.S. med spa market exceeds $10B and remains dominated by independent owner-operators running single locations. Thousands of profitable practices generating $500K–$2M in EBITDA are ripe for consolidation by buyers who can navigate CPOM compliance, standardize operations, and layer on shared services to create enterprise value well above individual unit multiples.
Individual med spas trade at 3.5–6x EBITDA. A multi-location platform with $5M+ EBITDA, centralized compliance infrastructure, and diversified provider teams commands 7–10x at exit. The arbitrage between acquisition multiples and exit multiples — combined with membership-driven recurring revenue — makes med spa one of the most attractive roll-up opportunities in lower middle market healthcare services.
Minimum $500K EBITDA
The platform anchor must generate at least $500K in owner-adjusted EBITDA with three years of clean financials, supporting SBA or institutional debt and demonstrating sustainable unit economics before scaling.
Systems-Driven Operations
Owner must not be the primary injector. Revenue should flow through an employed or contracted provider team, with documented SOPs for intake, treatment protocols, membership billing, and patient retention.
CPOM-Compliant Entity Structure
Platform location must have a clean medical director agreement, proper MSA structure separating the management and medical entities, and no history of regulatory violations or scope-of-practice enforcement actions.
Membership Revenue Base
A minimum of 200 active recurring members providing predictable monthly revenue demonstrates consumer loyalty and creates the subscription-like foundation required to underpin enterprise-level valuations at exit.
$300K+ EBITDA
Add-on targets should generate at least $300K in adjusted EBITDA, with revenue diversified across injectables, laser treatments, and skincare retail — reducing single-service concentration risk during integration.
Geographic Adjacency
Prioritize locations within 30–60 miles of existing platform units to enable shared medical director coverage, staff cross-utilization, centralized marketing spend, and efficient management oversight.
Active Patient Database of 1,000+
A documented database of 1,000+ active patients with visit history and average spend per client validates market penetration and provides immediate cross-sell opportunity within the expanding platform network.
Modern Equipment Inventory
Prioritize targets with equipment less than five years old or recently leased, minimizing near-term capex requirements and ensuring treatment menu alignment with the platform's standardized service offering.
Build your Med Spa roll-up
DealFlow OS surfaces off-market Med Spa targets with seller signals — the foundation of every successful roll-up.
Centralized Administrative Infrastructure
Consolidating billing, HR, compliance management, and vendor procurement across locations drives margin expansion of 300–500 basis points by eliminating redundant overhead at each individual unit.
Membership Program Standardization
Deploying a unified membership structure across all locations increases recurring revenue predictability, improves patient retention rates, and creates a platform-wide revenue floor that supports higher exit multiples.
Provider Recruitment and Retention Systems
Building a centralized injector and aesthetician recruiting pipeline reduces key-person dependency at individual locations and enables rapid staffing of newly acquired sites without disrupting revenue continuity.
Brand and Digital Marketing Scale
Centralizing SEO, paid social, and reputation management across locations reduces per-location customer acquisition costs and compounds local brand authority in target demographic markets faster than independent operators can achieve.
A well-constructed med spa platform of 6–12 locations with $5M–$10M in EBITDA and standardized operations typically exits to a national aesthetics roll-up, dermatology group, or private equity recapitalization at 7–10x EBITDA. Strong membership revenue, low provider concentration, and clean CPOM compliance documentation are the primary valuation drivers at exit. Target a 4–6 year hold period to allow full integration and EBITDA maturation before pursuing a strategic sale process.
Most institutional buyers target platforms with 5+ locations and $3M+ in platform EBITDA. Below that threshold, a strategic sale to a regional dermatology group or a secondary PE sponsor remains the most realistic exit path.
CPOM rules vary significantly by state. Each new state requires independent legal analysis, a locally licensed medical director, and a properly structured MSA. Engaging a healthcare regulatory attorney before entering any new state is non-negotiable.
Provider retention is the primary risk. Injectors and aestheticians carry personal client relationships. Structuring retention bonuses, employment agreements with reasonable non-competes, and clear career growth paths within the platform significantly reduces post-close revenue attrition.
Yes. Individual med spa acquisitions are SBA 7(a) eligible. However, SBA financing becomes less practical at scale. Most roll-up platforms transition to senior debt plus equity structures after the initial platform acquisition is stabilized.
More Med Spa Guides
DealFlow OS surfaces off-market platform targets with seller motivation scores. Free to join.
Find platform targets — freeNo credit card required
For Buyers
For Sellers